2Roudiere L, Viard JP. Osteonecrosis of the hip, lipodystrophy and antiretroviral treatment [ letter] [ J ]. AIDS, 2000,14 (13): 2056.
3Dusso A, Vidal M, Powderly WG, et al. Protease inhibitors inhibit in vitro conversion on 25 (OH)-vitamin D to 1,25 (OH) 2-vitamin D[abstract 030][C] .2nd International Workshop on Adverse Drug Reactions and Lipodystrophy, Toronto,2000 Sep, 13 - 15.
4Fagot JP, Mockenhaupt M, Bouwes-Bavnick JN, et al. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis [J]. AIDS,2001,15:1843 - 1848.
5Dybul M, Fauci AS, Bartlett JG, et al Guidelines for using antiretroviral agents among HIV-infected adults and adolescents[J ]. Ann Intern Med,2002,137(5pt2): 381 - 433.
7Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators [ J ]. N Eng1 J Med, 1998,338: 853 - 860.
8Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions[J]. Ann Intern Med, 1999; 131:81 - 87.
9Carr A, Cooper DA.Adverse effects of antiretroviral therapy [ J ].Lancet, 2000,356:1423 - 1430.
